21st May 2025 07:00
21 May 2025
Scancell Holdings plc
("Scancell" or the "Company")
Director Dealing
Scancell (AIM: SCLP), the developer of novel immunotherapy products for the treatment of multiple cancers, announces that Vulpes Testudo Fund, a fund closely associated with Martin Diggle, Non- Executive Director, has purchased 497,764 ordinary shares of 0.9p each ('Ordinary Shares') in the Company between 15 May 2025 and 20 May 2025 at a price of 9 pence per share. Following the purchase, Vulpes Life Science Fund and Vulpes Testudo Fund together hold 130,884,801 ordinary shares representing 12.62% of the company.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||||||
a) | Name | Vulpes Testudo Fund | |||||||||
2 | Reason for the notification | ||||||||||
a) | Position/status | Fund closely associated with Martin Diggle, Non-Executive Director | |||||||||
b) | Initial notification/Amendment | Initial notification | |||||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||||
a) | Name | Scancell Holdings plc | |||||||||
b) | LEI | 2138008RXEG856SNP666 | |||||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||||
a) | Description of the financial instrument, type of instrument | Ordinary Shares of 0.9 pence each | |||||||||
b) | Identification Code | GB00B63D3314 | |||||||||
c) | Nature of the transaction | Purchase of Ordinary Shares | |||||||||
d) | Price(s) and volume(s) |
| |||||||||
e) | Aggregated information - Aggregated volume - Price |
497,764 Ordinary Shares 9 pence per Ordinary Share | |||||||||
f) | Date of the transaction |
| |||||||||
g) | Place of the transaction | London Stock Exchange, AIM | |||||||||
For further information, please contact: | |
Scancell Holdings plc | +44 (0) 20 3709 5700 |
Phil L'Huillier, CEO | |
Sath Nirmalananthan, CFO | |
Dr Jean-Michel Cosséry, Non-Executive Chairman | |
Panmure Liberum (Nominated Adviser and Joint Broker) | +44 (0) 20 7886 2500 |
Emma Earl, Will Goode, Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking) | |
WG Partners LLP (Joint Broker) David Wilson, Claes Spang | +44 (0) 20 3705 9330
|
ICR Healthcare Mary-Jane Elliott, Stephanie Cuthbert, Chris Welsh | +44 (0) 20 3709 5700 |
About Scancell
Scancell (LSE:SCLP) develops immunotherapies for a Cancer-free future by enhancing long-lasting tumour specific immunity. As a clinical stage biotechnology company with deep roots in cancer immunology and translational research, Scancell develops tumour targeted off-the-shelf vaccines, with highly favourable safety and durable systemic immune responses. Scancell's lead product, iSCIB1+, a DNA vaccine, is currently showing strong promise on top of checkpoint therapies in a multi-arm phase 2 study in first-line melanoma. The second vaccine, Modi-1, is being investigated in a phase 2 study in a broad range of solid tumours. Scancell is also developing a pipeline of high affinity antibodies targeting tumour specific glycans using its proprietary platforms. Two of these antibodies are now being developed in major biopharma partnerships, and a further two antibodies targeting lung and epithelial cancers are actively being developed in-house.
https://www.scancell.co.uk
Related Shares:
Scancell Holdings